Jasper Therapeutics
JSPR
10 hedge funds and large institutions have $102M invested in Jasper Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 53 closing their positions.
26% more capital inflows, than outflows
Capital inflows: $104M | Capital outflows: $82.8M
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
56.95% less ownership
Funds ownership: 84.19% → 27.25% (-57%)
82% less funds holding
Funds holding: 56 → 10 (-46)
87% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Abingworth
London,
United Kingdom
|
+$57.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.3M |
| 4 |
Morgan Stanley
New York
|
+$1.11M |
| 5 |
Jane Street
New York
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mizuho Securities USA
New York
|
-$6.49M |
| 2 |
Tenor Capital Management
New York
|
-$4.97M |
| 3 |
Fir Tree Capital Management
New York
|
-$4.82M |
| 4 |
Shaolin Capital Management
Miami,
Florida
|
-$4.46M |
| 5 |
W.R. Berkley
Greenwich,
Connecticut
|
-$4.35M |
JSPR Hedge Fund Activity: Q3 2021 in Review
10 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2021, worth a combined $102M — up 22% from $83.7M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of JSPR and 7 opened new positions — a net loss of 46 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Abingworth, opening a new position worth an estimated $57.5M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $6.49M sold.
- 10 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2021, down from 56 in Q2 2021.
- Funds reported $102M of Jasper Therapeutics stock for Q3 2021, up 22% quarter-over-quarter.
- 7 funds opened new Jasper Therapeutics positions in Q3 2021 and 53 closed out, a net change of -46 holders.
- The largest Jasper Therapeutics buyer in Q3 2021 was Abingworth, an estimated $57.5M added.
- The largest Jasper Therapeutics seller in Q3 2021 was Mizuho Securities USA, an estimated $6.49M sold.
Based on aggregated 13F filings for Q3 2021.